1838-33-1

Upstream product

• 141-97-9 ethyl acetoacetate 
• 38624-62-3 ethyl 3-chloro-2-butenoate 
• 1215-13-0 3-(2-methoxy-phenoxy)-but-2-enoic acid ethyl ester 

Downstream Products

• 1191994-68-9 N-[1-(2-hydroxy-2-methyl-propyl)-1H-pyrazol-3-yl]-2-[4-(2-methoxy-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-3-(tetrahydropyran-4-yl)-propionamide 
• 1191997-15-5 (S)-2-[4-(2-methoxy-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-3-(tetrahydro-furan-2-yl)-propionic acid methyl ester 
• 1191997-10-0 (S)-3-cyclopentyl-2-[4-(2-methoxy-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-propionic acid methyl ester 
• 1191997-12-2 (S)-3-cyclohexyl-2-[4-(2-methoxy-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-propionic acid methyl ester 

Relevant academic research and scientific papers

PYRROLIDINONE GLUCOKINASE ACTIVATORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.